Gordon Wilkie

This inventor holds 4 USPTO granted patents and 2 published patent applications and 2 EPO patents. Top assignee: Blueprint Medicines Corporation. Active years: 2024-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Gordon Wilkie. Retrieved from https://idiyas.com/inventor/gordon-wilkie-eesyxv49

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 4 (Patent Applications = 2)

% Patents Active = 75.0

EPO Patents = 2 (Patent Applications = 4)

Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 3(Granted Patents)

Company Filing History:

4 out of 72

Blueprint Medicines Corporation

patents

Years Active: 2024-2026

Loading Chart...

4 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12655143 - Process for preparing an activin receptor-like kinase inhibitor (2026-06-16),

2. 12060354 - Crystalline forms of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making (2024-08-13),

3. 11999744 - Crystalline forms of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making (2024-06-04),

4. 11964980 - Crystalline forms of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1- f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making (2024-04-23),

Title: The Innovations of Gordon Wilkie in Pharmaceutical Science

Introduction

Gordon Wilkie, a notable inventor based in Cambridge, MA, has made significant contributions to the field of pharmaceutical sciences. With a total of three patents to his name, his work focuses on innovative methods of treating disorders linked with oncogenic alterations.

Latest Patents

Wilkie's latest patents explore crystalline forms of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine. These patents detail pharmaceutical compositions that involve pharmaceutically acceptable salts and solvates. Furthermore, they outline methods for treating conditions associated with oncogenic KIT and PDGFRA alterations. Innovative techniques for the synthesis of Compound (I) and its crystalline forms are also disclosed within these patents.

Career Highlights

Wilkie currently works at Blueprint Medicines Corporation, where his research contributes to cutting-edge developments in targeted cancer therapies. His career has been marked by a commitment to enhancing treatment options for patients affected by specific genetic alterations.

Collaborations

In his professional endeavors, Wilkie collaborates closely with his coworker Joshua D Waetzig. Their combined expertise in the field of pharmaceutical research fosters innovation and drives forward the mission of their organization.

Conclusion

Gordon Wilkie's pioneering work in the development of pharmaceutical compositions demonstrates his dedication to improving treatment methodologies for complex conditions. Through his innovative patents and collaborations, he continues to play a vital role in advancing therapeutic science.

Profile summary based on public USPTO records.